
Viewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition.
Brian Carlin is director QbD/Regulatory, DFE Pharma US

Viewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition.

February 2nd 2021